Michele Mercuri

May 20, 2023 | nejm.org | Pablo García-Pavía |Olivier Lairez |Michele Mercuri |Robert Frost

AbstractBackgroundTransthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the amelioration of cardiac dysfunction. NI006 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells.